{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:19Z","timestamp":1788985339514,"version":"build-2803163510"},"reference-count":164,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Tyrosine kinase 2 (TYK2) mediates the signaling pathways of proinflammatory cytokines such as interleukin (IL)-12, IL-23, and type I interferons (IFNs) and plays a pivotal role in the pathogenesis of psoriasis and various other immune-mediated diseases. Deucravacitinib, a selective oral TYK2 inhibitor, has been approved for the treatment of psoriasis and demonstrated high efficacy and a favorable safety profile. This review summarizes the potential for expanding deucravacitinib indications based on case reports, clinical trials, and preclinical studies. Diseases in which TYK2 pathway has been demonstrated to be involved and for which clinical benefit of deucravacitinib has been reported include discoid lupus erythematosus, systemic lupus erythematosus, alopecia areata, lichen planus, palmoplantar pustulosis, psoriatic arthritis, systemic sclerosis, interstitial pneumonia, inflammatory bowel disease, and chronic recurrent multifocal osteomyelitis. Furthermore, emerging research suggests potential therapeutic applications in neurodegenerative diseases such as Alzheimer\u2019s disease, and malignancies such as type 1 diabetes, vascular calcification in chronic kidney disease, T-cell acute lymphoblastic leukemia, and multiple sclerosis. Deucravacitinib may exert therapeutic effects by broadly suppressing cytokine signaling in a diverse range of inflammatory disorders. Ongoing clinical trials and mechanistic studies are required to clarify the efficacy and support its future indications.<\/jats:p>","DOI":"10.3390\/ijms26199447","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:54:48Z","timestamp":1759229688000},"page":"9447","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Review of Promising Off-Label Use of Deucravacitinib"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4832-1899","authenticated-orcid":false,"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo 164-8541, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo 164-8541, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-4355","authenticated-orcid":false,"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tokyo Metropolitan Police Hospital, Tokyo 164-8541, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"117114","DOI":"10.1016\/j.ejmech.2024.117114","article-title":"Tyrosine kinase 2 inhibitors: Synthesis and applications in the treatment of autoimmune diseases","volume":"283","author":"Pan","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rusi\u00f1ol, L., and Puig, L. (2023). Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043391"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.immuni.2009.03.013","article-title":"Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-gamma and interleukin-12","volume":"30","author":"Schulz","year":"2009","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., and Guggino, G. (2021). Role of the IL-23\/IL-17 Pathway in Rheumatic Diseases: An Overview. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637829"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: Exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/1346-8138.15913","article-title":"Pathophysiology of psoriasis: A review","volume":"48","author":"Yamanaka","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/1744666X.2022.2008240","article-title":"TYK2 inhibition: Changing the treatment landscape for psoriasis?","volume":"18","author":"Abduelmula","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/1346-8138.17074","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial","volume":"51","author":"Imafuku","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1346-8138.17570","article-title":"Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study","volume":"52","author":"Tada","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","article-title":"Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan","volume":"35","author":"Hagino","year":"2024","journal-title":"J. Dermatolog Treat."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kaczmarska, A., Kwiatkowska, D., Skrzypek, K.K., Kowalewski, Z.T., Jaworecka, K., and Reich, A. (2023). Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914734"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/1346-8138.17617","article-title":"Real-world 52-week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index","volume":"52","author":"Hagino","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1346-8138.17601","article-title":"Predictive factors for responders to deucravacitinib treatment in patients with psoriasis","volume":"52","author":"Hagino","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2024.09.060","article-title":"Response to deucravacitinib in psoriasis patients with prior biologic therapy failures: A retrospective study","volume":"92","author":"Lovell","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/1346-8138.17665","article-title":"Long-term real-world effectiveness of deucravacitinib in psoriasis: A 52-week prospective study stratified by prior apremilast or biologic therapy","volume":"52","author":"Hagino","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1007\/s13555-025-01463-6","article-title":"Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis","volume":"15","author":"Papp","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ced\/llae312","article-title":"Effectiveness of deucravacitinib for genital, nail and scalp lesions in patients with psoriasis: A 24-week real-world study","volume":"50","author":"Hagino","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/ced\/llae530","article-title":"Long-term effectiveness and safety of deucravacitinib for psoriasis: A 52-week real-world study of genital, scalp and nail lesions","volume":"50","author":"Hagino","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.4049\/jimmunol.176.12.7263","article-title":"Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation","volume":"176","author":"Shaw","year":"2006","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bang, C.H., Park, C.J., and Kim, Y.S. (2025). The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051745"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103440","DOI":"10.1016\/j.autrev.2023.103440","article-title":"Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis","volume":"22","author":"Ma","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jdcr.2024.04.032","article-title":"Discoid lupus erythematosus successfully treated with deucravacitinib","volume":"49","author":"Ezeh","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_36","first-page":"1","article-title":"Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report","volume":"13","author":"Aw","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: An emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic Lupus Erythematosus: A Review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: Diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103723","DOI":"10.1016\/j.autrev.2024.103723","article-title":"Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules\u2014A systematic review and meta-analysis","volume":"24","author":"Bokor","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u2018Not at target\u2019: Prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study","volume":"24","author":"Louthrenoo","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","article-title":"Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls","volume":"60","author":"Bultink","year":"2021","journal-title":"Rheumatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","first-page":"364","article-title":"Alopecia areata: Autoimmune basis of hair loss","volume":"14","author":"Alexis","year":"2004","journal-title":"Eur. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2005.07.001","article-title":"Alopecia areata: A tissue specific autoimmune disease of the hair follicle","volume":"5","author":"Gilhar","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-0625.2011.01427.x","article-title":"Alopecia areata as a model for T cell-dependent autoimmune diseases","volume":"21","author":"Bertolini","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Van Acker, M.M., Schwartz, R.R., Andrews, K., Seiffert-Sinha, K., and Sinha, A.A. (2023). Inheritance-Specific Dysregulation of Th1- and Th17-Associated Cytokines in Alopecia Areata. Biomolecules, 13.","DOI":"10.3390\/biom13091285"},{"key":"ref_55","first-page":"1","article-title":"Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report","volume":"11","author":"Oliel","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yan, D., Fan, H., Chen, M., Xia, L., Wang, S., Dong, W., Wang, Q., Niu, S., Rao, H., and Chen, L. (2022). The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.950450"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Pavel","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: Clinical overview and molecular basis","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e15080","DOI":"10.1111\/exd.15080","article-title":"TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus","volume":"33","author":"Stolte","year":"2024","journal-title":"Exp. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"eaav7561","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The inflammation in cutaneous lichen planus is dominated by IFN-\u03d2 and IL-21-A basis for therapeutic JAK1 inhibition","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaci.2018.02.044","article-title":"TH1\/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus","volume":"142","author":"Schmidt","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","first-page":"1409","article-title":"TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases","volume":"19","author":"Ghoreschi","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar pustulosis: Recent advances in etiopathogenesis and emerging treatments","volume":"21","author":"Zozula","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","article-title":"Psoriasis: From pathogenesis to targeted therapies","volume":"54","author":"Conrad","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2399220","DOI":"10.1080\/09546634.2024.2399220","article-title":"Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis","volume":"35","author":"Papara","year":"2024","journal-title":"J. Dermatolog Treat."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo","year":"2019","journal-title":"F1000Res"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101670","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","volume":"35","author":"Kishimoto","year":"2021","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2023-2-7","DOI":"10.7573\/dic.2023-2-7","article-title":"Deucravacitinib for the treatment of psoriatic arthritis: The evidence so far","volume":"12","author":"Martins","year":"2023","journal-title":"Drugs Context"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","article-title":"Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial","volume":"64","author":"Kavanaugh","year":"2025","journal-title":"Rheumatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1: Localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: A prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","article-title":"New promising drugs for the treatment of systemic sclerosis: Pathogenic considerations, enhanced classifications, and personalized medicine","volume":"30","author":"Lescoat","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/kjm2.12505","article-title":"Pathophysiology of systemic sclerosis (scleroderma)","volume":"38","author":"Rosendahl","year":"2022","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/rheumatology\/38.7.612","article-title":"Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis","volume":"38","author":"Hasegawa","year":"1999","journal-title":"Rheumatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.170.3.727","article-title":"Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation","volume":"170","author":"Khalil","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0167-5699(94)90021-3","article-title":"Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells","volume":"15","author":"Zurawski","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5493\/wjem.v7.i3.84","article-title":"Treg\/Th17 cell balance and phytohaemagglutinin activation of T lymphocytes in peripheral blood of systemic sclerosis patients","volume":"7","author":"Krasimirova","year":"2017","journal-title":"World J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00296-018-4071-8","article-title":"Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis","volume":"38","author":"Tang","year":"2018","journal-title":"Rheumatol. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s12276-022-00860-7","article-title":"Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin","volume":"54","author":"Park","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1093\/rheumatology\/keaf019","article-title":"The effects of deucravacitinib on three cases of systemic sclerosis associated with psoriasis","volume":"64","author":"Fukasawa","year":"2025","journal-title":"Rheumatology"},{"key":"ref_90","first-page":"173","article-title":"Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life","volume":"8","author":"Faust","year":"2012","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: Current state of the art","volume":"13","author":"Fiocchi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00365521.2018.1447597","article-title":"Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies","volume":"53","author":"Ahluwalia","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000546640","article-title":"Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis","volume":"10","author":"Akiyama","year":"2025","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12014-024-09511-7","article-title":"Identification of novel proteins in inflammatory bowel disease based on the gut-brain axis: A multi-omics integrated analysis","volume":"21","author":"Xu","year":"2024","journal-title":"Clin. Proteom."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"Danese","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Samarelli, A.V., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., Manicardi, L., Moretti, A., and Tabb\u00ec, L. (2021). Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168952"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Montero, P., Milara, J., Roger, I., and Cortijo, J. (2021). Role of JAK\/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126211"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic Pulmonary Fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12931-020-1319-0","article-title":"TGF-\u03b2 pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling","volume":"21","author":"Brook","year":"2020","journal-title":"Respir. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/CCID.S536534","article-title":"Deucravacitinib Improved Interstitial Pneumonia Along with KL-6 Reduction in a Patient with Psoriasis: A Case Report","volume":"18","author":"Mima","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/DDDT.S353494","article-title":"Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease","volume":"16","author":"Huo","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Sergi, C.M., Miller, E., Demellawy, D.E., Shen, F., and Zhang, M. (2022). Chronic recurrent multifocal osteomyelitis. A narrative and pictorial review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.959575"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11914-017-0405-9","article-title":"Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment","volume":"15","author":"Hofmann","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MOP.0000000000000970","article-title":"Chronic recurrent multifocal osteomyelitis: Diagnosis and treatment","volume":"33","author":"Perea","year":"2021","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00296-016-3466-7","article-title":"Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO)","volume":"36","author":"Hofmann","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clim.2012.07.012","article-title":"Attenuated TLR4\/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression","volume":"145","author":"Hofmann","year":"2012","journal-title":"Clin. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/art.39013","article-title":"A large national cohort of French patients with chronic recurrent multifocal osteitis","volume":"67","author":"Wipff","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_119","first-page":"459","article-title":"The jigsaw puzzle of chronic non-bacterial osteomyelitis: Are anti-IL17 therapies the next piece?","volume":"59","author":"Goenka","year":"2020","journal-title":"Rheumatology"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Glatzel, C., Strunz, P.P., Goebeler, M., Holl-Wieden, A., Schmalzing, M., and Schmieder, A. (2025). Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1480810"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Xu, J., Yu, L., Liu, F., Wan, L., and Deng, Z. (2023). The effect of cytokines on osteoblasts and osteoclasts in bone remodeling in osteoporosis: A review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1222129"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.immuni.2022.10.016","article-title":"Emerging roles of innate and adaptive immunity in Alzheimer\u2019s disease","volume":"55","author":"Chen","year":"2022","journal-title":"Immunity"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"eaaz4699","DOI":"10.1126\/scitranslmed.aaz4699","article-title":"Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss","volume":"13","author":"Rodriguez","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, L.E., Rodriguez, S., Hug, C., Daneshvari, S., Chung, A., Bradshaw, G.A., Sahin, A., Zhou, G., Eisert, R.J., and Piccioni, F. (2024). TYK2 as a novel therapeutic target in Alzheimer\u2019s Disease with TDP-43 inclusions. bioRxiv.","DOI":"10.1101\/2024.06.04.595773"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tins.2025.01.004","article-title":"Deciphering the role of TYK2 in tau phosphorylation and pathology","volume":"48","author":"Bowles","year":"2025","journal-title":"Trends Neurosci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41593-024-01777-2","article-title":"TYK2 regulates tau levels, phosphorylation and aggregation in a tauopathy mouse model","volume":"27","author":"Kim","year":"2024","journal-title":"Nat. Neurosci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/alz.12452","article-title":"Current directions in tau research: Highlights from Tau 2020","volume":"18","author":"Sexton","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MNH.0000000000000507","article-title":"An overview of the mechanisms in vascular calcification during chronic kidney disease","volume":"28","author":"Voelkl","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/CS20190895","article-title":"Inflammation: A putative link between phosphate metabolism and cardiovascular disease","volume":"135","author":"Voelkl","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2019.04.006","article-title":"IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2","volume":"124","author":"Kurozumi","year":"2019","journal-title":"Bone"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.kint.2024.07.011","article-title":"Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification","volume":"106","author":"Alesutan","year":"2024","journal-title":"Kidney Int."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/jcb.25088","article-title":"Oncostatin M Promotes Osteoblastic Differentiation of Human Vascular Smooth Muscle Cells Through JAK3-STAT3 Pathway","volume":"116","author":"Kakutani","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e027222","DOI":"10.1161\/JAHA.122.027222","article-title":"Interleukin-29 Accelerates Vascular Calcification via JAK2\/STAT3\/BMP2 Signaling","volume":"12","author":"Hao","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.it.2019.08.003","article-title":"Rebalancing Immune Homeostasis to Treat Autoimmune Diseases","volume":"40","author":"Horwitz","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ng.3245","article-title":"Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers","volume":"47","author":"Chen","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Bradfield, J.P., Qu, H.Q., Wang, K., Zhang, H., Sleiman, P.M., Kim, C.E., Mentch, F.D., Qiu, H., Glessner, J.T., and Thomas, K.A. (2011). A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1002293"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41467-024-45573-9","article-title":"TYK2 signaling promotes the development of autoreactive CD8+ cytotoxic T lymphocytes and type 1 diabetes","volume":"15","author":"Mine","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Dos Santos, R.S., Guzman-Llorens, D., Perez-Serna, A.A., Nadal, A., and Marroqui, L. (2023). Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-\u03b2H1 \u03b2-cells against proinflammatory insults. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1263926"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2021.02.011","article-title":"Type I interferons as key players in pancreatic \u03b2-cell dysfunction in type 1 diabetes","volume":"359","author":"Marroqui","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2017.02.002","article-title":"Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress","volume":"80","author":"Lombardi","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00125-017-4536-4","article-title":"IFN-\u03b1 induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells","volume":"61","author":"Marroqui","year":"2018","journal-title":"Diabetologia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41467-020-16327-0","article-title":"An integrated multi-omics approach identifies the landscape of interferon-\u03b1-mediated responses of human pancreatic beta cells","volume":"11","author":"Colli","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","article-title":"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia","volume":"3","author":"Sanda","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/leu.2016.277","article-title":"Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences","volume":"31","author":"Waanders","year":"2017","journal-title":"Leukemia"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0092-8674(91)90361-2","article-title":"bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes","volume":"67","author":"Sentman","year":"1991","journal-title":"Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14563","article-title":"Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia","volume":"177","author":"Akahane","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1468-1331.2007.01882.x","article-title":"Prevalence of autoimmune thyroid disorders in a Spanish multiple sclerosis cohort","volume":"14","author":"Munteis","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"104903","DOI":"10.1016\/j.msard.2023.104903","article-title":"Establishment of comorbidity target pools and prediction of drugs candidate for multiple sclerosis and autoimmune thyroid diseases based on GWAS and transcriptome data","volume":"78","author":"Wang","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.2741\/3908","article-title":"Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity","volume":"16","author":"Strobl","year":"2011","journal-title":"Front. Biosci. Landmark Ed"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"11594","DOI":"10.1073\/pnas.1930781100","article-title":"A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q\/J mice to infection and autoimmunity","volume":"100","author":"Shaw","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J. Immunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/emboj\/cdg038","article-title":"The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression","volume":"22","author":"Ragimbeau","year":"2003","journal-title":"EMBO J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2025.05.007","article-title":"Dissecting key contributions of TH2 and TH17 cytokines to atopic dermatitis pathophysiology","volume":"156","author":"Meesters","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/1346-8138.16691","article-title":"English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)","volume":"50","author":"Saeki","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ijc.34180","article-title":"Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk","volume":"151","author":"Yarmolinsky","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acsmedchemlett.4c00004","article-title":"Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders","volume":"15","author":"Kargbo","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Qiu, J., Liu, J., Liu, W., Lin, F., and Shi, N. (2023). The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1264667"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9447\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:03:25Z","timestamp":1759230205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":164,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199447"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199447","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]}}}